

STATEMENT OF STANDALONE UNAUDITED RESULTS
PART I
FOR THE QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2013

Sl. No.	Particulars	Rs. in Lakhs				
		3 Months ended 31.12.2013	Preceding 3 months ended 30.09.2013	Corresponding 3 Months ended 31.12.2012 in the previous year	Year to date figures for the current period ended 31.12.2013	Previous year ended 31.12.2012
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Income from operations	(1)	(2)	(3)	(4)	(5)
	(a) Net Sales / Income from Operations (Net of excise duty)	24,024.33	19,918.13	15,209.06	75,159.73	61,328.85
	(b) Other Operating Income	1,313.25	976.07	2,535.36	5,551.72	9,871.84
	Total Income from operations (net)	25,337.58	20,894.20	17,744.42	80,711.45	71,200.69
2	Expenses					
	(a) Cost of material consumed	13,217.32	8,358.06	6,954.21	35,229.69	28,154.17
	(b) Purchases of stock-in-trade	3,864.99	4,588.50	2,620.05	13,181.60	10,030.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,316.98)	(703.59)	210.76	(1,380.92)	667.59
	(d) Employee Benefit expenses	1,968.71	1,961.47	2,298.48	7,598.53	7,091.94
	(e) Depreciation and amortisation expense	971.21	929.93	588.11	3,706.37	1,909.87
	(f) Other expenses	4,838.36	3,172.19	4,779.26	14,381.27	15,685.70
	Total expenses	23,543.61	18,306.56	17,450.87	72,716.54	63,539.98
3	Profit/(Loss) from Operations before Other Income, finance cost & Exceptional Items (1-2)	1,793.97	2,587.64	293.55	7,994.91	7,660.71
4	Other Income	138,823.86	1,652.78	8,386.95	143,905.85	11,890.76
5	Profit/(Loss) from ordinary activities before finance cost & Exceptional Items (3+4)	140,617.83	4,240.42	8,680.50	151,900.76	19,551.47
6	Finance costs	3,990.53	2,512.26	887.96	9,342.45	7,121.97
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	136,627.30	1,728.16	7,792.54	142,558.31	12,429.50
8	Exceptional Items:					
	- Exchange Fluctuation (loss) / gain (Net)	2,712.78	(1,186.66)	(12.98)	366.30	(6,465.33)
	- Net gain on sale of long term Investments	326,552.67	-	3.51	326,552.67	3.51
	- Write down of Inventory	(1,618.94)	-	-	(1,618.94)	-
9	Profit / (Loss) from Ordinary Activities before tax (7+ 8)	464,273.81	541.50	7,783.07	467,858.34	5,988.59
10	Tax Expense / (credit)	111,749.68	320.00	390.00	111,739.69	390.00
11	Net Profit / (Loss) after tax (9-10)	352,524.13	221.50	7,393.07	356,118.65	5,598.59

STATEMENT OF STANDALONE UNAUDITED RESULTS
PART I
FOR THE QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2013

Particulars	3 Months ended 31.12.2013	Preceding 3 months ended 30.09.2013	Corresponding 3 Months ended 31.12.2012 in the previous year	Year to date figures for the current period ended 31.12.2013	Previous year ended 31.12.2012
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
	(1)	(2)	(3)	(4)	(5)
12 Paid-up Equity Share Capital (Face value of Rs.10/-each)	5,956.56	5,916.14	5,880.37	5,956.56	5,880.37
13 Reserves excluding revaluation reserves					131,260.96
14 Earnings per share (face value of Rs. 10/- each) - not annualised					
(a) Basic EPS (Rs.)	597.00	0.38	12.58	602.79	9.55
(b) Diluted EPS (Rs.)	595.12	0.37	12.46	599.85	5.84

PART II
SELECT INFORMATION FOR THE QUARTER AND TWELVE MONTH ENDED DECEMBER 31, 2013

Particulars	3 Months ended 31.12.2013	Preceding 3 months ended 30.09.2013	Corresponding 3 Months ended 31.12.2012 in the previous year	Year to date figures for the current period ended 31.12.2013	Previous year ended 31.12.2012
A PARTICULARS OF SHAREHOLDING					
1 Public shareholding :					
(a) Number of shares	43,381,419	42,977,169	42,629,519	43,381,419	42,629,519
(b) Percentage of shareholding	72.83%	72.64%	72.49%	72.83%	72.49%
2 Promoters and Promoter group shareholding :					
(a) Pledged / Encumbered					
- Number of shares	1,876,667	7,280,152	7,201,786	1,876,667	7,201,786
- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	11.60%	44.98%	44.53%	11.60%	44.53%
- Percentage of shareholding (as a % of the total share capital of the Company)	3.15%	12.31%	12.25%	3.15%	12.25%
(b) Non Pledged / Non Encumbered					
- Number of shares	14,307,535	8,904,050	8,972,416	14,307,535	8,972,416
- Percentage of shareholding (as a % of the total share holding of promoter and promoter group)	88.40%	55.02%	55.47%	88.40%	55.47%
- Percentage of shareholding (as a % of the total share capital of the Company)	24.02%	15.05%	15.26%	24.02%	15.26%

Particulars	3 Months ended 31.12.2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	33
Disposed of during the quarter	30
Remaining unresolved at the end of the quarter	3

STATEMENT OF ASSETS AND LIABILITIES
AS AT DECEMBER 31, 2013

Particulars		Rs In Lakhs	
	As at 31.12.2013	As of previous year ended 31.12.2012	
	UNAUDITED	AUDITED	
A EQUITY AND LIABILITIES			
1 Shareholder's funds			
a. Share Capital	5,956.56	5,880.37	
b. Reserves and surplus	164,614.43	131,260.61	
Sub-total of Shareholder's fund	170,570.99	137,140.98	
2 Non-current liabilities			
a. Long-term borrowings	25,331.11	28,466.10	
b. Other long-term liabilities	616.32	799.45	
c. Deferred tax liabilities	439.00	-	
c. Long-term provisions	1,518.49	5,042.91	
Sub-total - Non-current liabilities	27,904.92	34,308.46	
3 Current liabilities			
a. Short-term borrowings	38,574.26	29,358.10	
b. Trade payables	20,468.22	14,293.82	
c. Other current liabilities	13,889.61	11,042.68	
d. Short-term provisions	24,825.55	3,733.86	
Sub-total - Current liabilities	97,757.64	58,428.46	
TOTAL - EQUITY AND LIABILITIES	296,233.55	229,877.90	
B ASSETS			
1 Non-current assets			
a. Fixed assets	52,151.17	33,582.77	
b. Non-current investments	63,634.96	129,532.37	
c. Long-term loans and advances	13,215.42	9,225.84	
Sub-total - Non-current assets	129,001.55	172,340.98	
2 Current assets			
a. Current investments	47,174.44	3.81	
b. Inventories	12,555.75	10,435.29	
c. Trade receivables	24,974.43	19,309.56	
d. Cash and cash equivalents	57,367.90	2,932.95	
e. Short-term loans and advances	23,751.12	23,431.56	
f. Other current assets	1,408.36	1,423.75	
Sub-total - Current assets	167,232.00	57,536.92	
TOTAL - ASSETS	296,233.55	229,877.90	

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2013**

Notes:

- 1 The above unaudited results of the Company has been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on February 7, 2014.
- 2 The statutory auditors have carried out limited review of the above standalone results.
- 3 The previous period's figures have been regrouped/ reclassified wherever necessary to conform to the classification of the current period.
- 4 In terms of the scheme of arrangement approved by the Hon'ble High Courts of Judicature during the year ended December 31, 2009, the Company had created a Reserve for Business Restructure (BR) which has been utilised during prior years as mentioned below

Particulars	3 Months ended 31.12.2013	Preceding 3 months ended 30.09.2013	Corresponding 3 Months ended 31.12.2012 in the previous year	Year to date figures for the current period ended 31.12.2013	Previous year ended 31.12.2012
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Utilisation of BR :					
- Employee benefit expenses accrued / (reversed) - net	-	-	(452.65)	-	397.37
- Depreciation and Amortisation	-	-	426.74	-	1,699.78
- Other expenses	-	-	371.90	-	534.50
- Interest on Fixed Loans	-	-	835.85	-	1,886.46
Impact if the Company followed the Accounting Standards instead of the accounting treatment provided in the Scheme :-					
Net Profit for the period would have decreased by :	-	-	1,181.84	-	4,518.11
Earnings / (Loss) per share (EPS) (Face value of Rs.10/-each) would have been :					
- Basic (not annualised)	Rs. 597.00	Rs. 0.38	Rs. 10.56	Rs. 602.79	Rs. 1.84
- Diluted (not annualised)	595.12	0.37	10.47	599.85	(1.37)

5 During the quarter, 404,250 equity shares were allotted by the Company [203,750 shares under Strides Arcolab ESOP 2006 Scheme, 160,500 shares under Strides Arcolab ESOP 2008 and 40,000 shares under Strides Arcolab ESOP 2008 (Director) Scheme] on exercising equal number of options. No options were granted in the current period.

6 During the quarter ended March 2013 (February 27, 2013), the Company and its subsidiary, Agila Specialties Asia Pte. Limited, (Agila Asia), had entered into definitive agreements for the sale of entities into Specialty products (a part of the Pharmaceutical business that the Group is into) by way of share sales to Wydon Inc. (the "Purchaser"). In the current quarter (on December 5, 2013), the Company has completed such sale of shares in Agila Specialties Private Limited (AGILA) and in Agila Specialties Global Asia Pte. Limited (Agila Global). Exceptional items in the above results include profit from sale of investments in AGILA to the extent of Rs. 326,552.67 Lakhs net of transaction costs and special bonus of Rs. 10,725.77 Lakhs.

FOR THE QUARTER AND TWELVE MONTHS ENDED DECEMBER 31, 2013


Consequent to the above, with effect from 5th December 2013, following entities ceases to be the subsidiaries of the Strides Group:

- a) Agila Specialties Private Limited, India.
- b) Onco Therapies Limited, India
- c) Agila Specialties Global Pte Ltd, Singapore
- d) Agila Australia Pty Ltd, Australia
- e) Agila (NZ) Pty Ltd, New Zealand
- f) Calatist Pty Ltd, Australia
- g) Agila Specialties Americas Ltd, Cyprus
- h) Agila Farmaceutica Participacoes Ltd, Brazil
- i) Agila Especialidades Farmaceuticas Ltda, Campos
- j) Agila Marketing e Distribucao De Produtos Hospitales Ltda, Brazil
- k) Agila Specialties Inc, USA
- l) Sagent Agila LLC
- m) Agila Specialties Pharma Corporation, Canada
- n) Agila - Jamp JV
- o) Agila Specialties (Holdings), Cyprus
- p) Onco Laboratories Ltd, Cyprus
- q) Farma Plus, Norway
- r) Agila Specialties Ltd, Poland
- s) Agila Specialties UK Ltd, UK
- t) Agila Specialties Investments, UK

- 8 The Board of Directors of the Company in the Meeting held on December 10, 2013 have approved change of financial year of the Company from January-December to that of April-March. Consequently, the current financial year will be for a period of 15 months i.e., from January 1, 2013 to March 31, 2014
- 9 The Board of Directors of the Company in the Meeting held on December 10, 2013 declared a special dividend of Rs.500/- per share.
- 10 Exchange fluctuation gain/loss (net) included under Exceptional Items comprises the exchange gain / loss arising on account of restatement and settlement of long term foreign currency loans and intra-group loans given, profit / loss on disposal of non-current investments and gain/ loss on related derivative contracts.
- 11 Write down of inventory considered under exceptional items relates to products which are discontinued.
- 12 The Company's operations fall within a single business segment viz. "Pharmaceutical Products" and as such there is no reportable segment information as per Accounting Standard 17 issued under the relevant provisions of the Companies Act, 1956.

lu.

Bangalore, February 07, 2014

For and on behalf of the Board



Arun Kumar
Executive Vice Chairman & Managing Director

**INDEPENDENT AUDITORS' REVIEW REPORT
TO THE BOARD OF DIRECTORS OF
STRIDES ARCOLAB LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **STRIDES ARCOLAB LIMITED** (the "Company") for the quarter and twelve months ended December 31, 2013 (the 'Statement'), being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part II – Select Information referred to in paragraph 5 below. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The Company has early adopted Accounting Standard (AS) 30 'Financial Instruments: Recognition and Measurement', AS 31 'Financial Instruments: Presentation' and AS 32 'Financial Instruments: Disclosure', to the extent such standards do not conflict with the standards notified under section 211(3C) of the Companies Act.
4. Further to our comments in paragraph 3 above and based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards notified under the Companies Act, 1956 (which continue to be applicable in respect of Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs) and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Further, we also report that we have traced the number of shares as well as the percentage of shareholding in respect of the aggregate amount of public shareholding and the number of shares as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoter group shareholding in terms of Clause 35 of the Listing Agreements and the particulars relating to investor complaints disclosed in Part II - Select Information for the quarter and twelve months ended December 31, 2013 of the Statement, from the details furnished by the Management.

For **DELOITTE HASKINS & SELLS**

Chartered Accountants
(Registration No. 008072S)



V. Srikumar
Partner

(Membership No. 84494)

Press Release

**Global Pharma business meets YTD Dec '13 Guidance,
Revenues at INR 1,035 Crores with an EBITDA of INR 201 Crores***

Current Financial Year extended by 3 months, to end in Mar'14

**Guides Revenues of INR 280 Crores and EBITDA in the range of
INR 58-60 Crores for the extended quarter ending Mar '14**

*Adjusted for Exchange, YTD Dec'13 EBITDA at INR 223 Crs

Bangalore, February 7, 2014 Strides Arcolab (BSE: 532531, NSE: STAR) today announced its financial results for the Quarter ended December 31, 2013.

Highlights


Source: Management Accounts

Global Pharma

- Three notch upgrade from BBB+ to A+ (in Jan'14) by India Ratings (a Fitch Group company)
- Revenue Guidance of Rs. 1,000 Crs & EBITDA guidance of Rs. 200 Crs met despite delays in anticipated product approvals from USFDA
- Consolidated Pharma Revenues for YTD Dec'13 at Rs.1,035 Crores with an EBITDA of Rs.201 Crores, impacted by an Exchange Loss of Rs.22 Crores (EBITDA Margin of 19%)
- Adjusted for Exchange Loss, YTD Dec'13 EBITDA at Rs.223 Crores, EBITDA Margin of 22%
- Q4'13 Consolidated Pharma Revenues at Rs.326 Crores with an EBITDA of Rs.60 Crores
- Q4'13 Consolidated Pharma EBITDA grew by 100+% (Rs.60 Crores in Q4 2013 against Rs.28 Crores in Q4 2012)
- Strong offtake in Institutional business with the launch of recently approved Anti-Malarial product
- 47 filings as on date with USFDA with 18 pending approvals

Biotech

- Stelis Biopharma entered into a long-term agreement with Germany's Pieris AG for worldwide development and commercialisation of a protein molecule, primarily focused on ophthalmology.



“This has been a defining quarter for all of us at Strides as we delivered significant value to all stakeholders post the successful completion of the Agila transaction. The continuing global pharma business has delivered the 12 month guidance despite delays in key product approvals from USFDA. We expect to continue the momentum in the coming quarters.” said Arun Kumar, Vice Chairman and Group CEO, Strides Arcolab Limited.

Standalone Financials

	(Rupees in Crores)		
	YTD Dec '13	YTD Dec '12	Growth %
Revenues	876	774	13%
EBITDA	186	158	18%
PBT	4,679	60	100+%
PAT	3,561	56	100+%
EPS	Rs.602.79	Rs. 9.55	100+%

	(Rupees in Crores)		
	Q4 '13	Q4'12	Growth %
Revenues	276	229	20%
EBITDA	50	61	-17%
PBT	4,643	78	100+%
PAT	3,525	74	100+%
EPS	Rs.597	Rs.12.58	100+%

Source: unaudited standalone financials


Note: Financial year changed from Jan-Dec to April-March in line with the new Companies Act. Current Financial year will be for 15 months ending March 2014

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets.

Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

<u>Strides</u> Badree Komandur, CFO +91 80 6784 0747 <u>Investors:</u> Mr. Kannan. N: +91 98450 54745 Mr. Vikesh Kumar +91 80 6784 0827	<u>PR Consultancy</u> Weber Shandwick Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com Mahesh Nair: +91 98803 76648 MNair@webershandwick.com
---	--

